Myocardial Reverse Remodeling

Cardiovascular Therapeutics

Volumn 30, Issue 3, 2012, Pages 172-181

  Hellawell, Jennifer L ^a   Margulies, Kenneth B ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Cardiomyopathy; Heart failure; Hypertrophy; Ischemic heart disease; Remodeling

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANDESARTAN; ENALAPRIL; SPIRONOLACTONE; VALSARTAN;

AORTA STENOSIS; AORTA VALVE REPLACEMENT; CARDIAC IMAGING; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOMYOPATHY; DEVICE THERAPY; HEART FAILURE; HEART FUNCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HEART VALVE SURGERY; HEART VENTRICLE HYPERTROPHY; HUMAN; ISCHEMIC HEART DISEASE; LEFT VENTRICULAR ASSIST DEVICE; METHODOLOGY; MITRAL VALVE REGURGITATION; MITRAL VALVE REPAIR; MITRAL VALVE REPLACEMENT; MYOCARDIAL REVERSE REMODELING; MYOCARDITIS; PERIPARTUM CARDIOMYOPATHY; POSITIVE END EXPIRATORY PRESSURE; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SYSTOLIC HEART FAILURE;

ANIMALS; CARDIOMEGALY; HEART DISEASES; HUMANS; MYOCARDIUM; RECOVERY OF FUNCTION; TREATMENT OUTCOME; VENTRICULAR REMODELING;

EID: 84856402468     PISSN: 17555914     EISSN: 17555922     Source Type: Journal    
DOI: 10.1111/j.1755-5922.2010.00247.x     Document Type: Review

References (120)

1. Konstam MA. Reliability of ventricular remodeling as a surrogate for use in conjunction with clinical outcomes in heart failure. Am J Cardiol 2005;96:867-871.
2. Udelson JE, Konstam MA. Relation between left ventricular remodeling and clinical outcomes in heart failure patients with left ventricular systolic dysfunction. J Card Fail 2002;8:S465-S471.
3. Codina M, Elser J, Margulies KB. Current status of stem cell therapy in heart failure. Curr Cardiol Rep 2010;12:199-208.
4. Abboud J, Murad Y, Chen-Scarabelli C, Saravolatz L, Scarabelli TM. Peripartum cardiomyopathy: A comprehensive review. Int J Cardiol 2007;118:295-303.
5. McCarthy RE, 3rd, Boehmer JP, Hruban RH, Hutchins GM, Kasper EK, Hare JM, Baughman KL. Long-term outcome of fulminant myocarditis as compared with acute (nonfulminant) myocarditis. New Engl J Med 2000;342:690-695.
6. Kodama M, Oda H, Okabe M, Aizawa Y, Izumi T. Early and long-term mortality of the clinical subtypes of myocarditis. Jpn Circ J 2001;65:961-964.
7. Chau EM, Chow WH, Chiu CS, Wang E. Treatment and outcome of biopsy-proven fulminant myocarditis in adults. Int Journal Cardiol 2006;110:405-406.
8. La Vecchia LL, Bedogni F, Bozzola L, Bevilacqua P, Ometto R, Vincenzi M. Prediction of recovery after abstinence in alcoholic cardiomyopathy: Role of hemodynamic and morphometric parameters. Clin Cardiol 1996;19:45-50.
9. Cardinale D, Colombo A, Lamantia G, et al. Anthracycline-induced cardiomyopathy: Clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol 2010;55:213-220.
10. Chu TF, Rupnick MA, Kerkela R, et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 2007;370:2011-2019.
11. Keefe DL. Trastuzumab-associated cardiotoxicity. Cancer 2002;95:1592-1600.
12. Grogan M, Smith HC, Gersh BJ, Wood DL. Left ventricular dysfunction due to atrial fibrillation in patients initially believed to have idiopathic dilated cardiomyopathy. Am J Cardiol 1992;69:1570-1573.
13. Watanabe H, Okamura K, Chinushi M, Furushima H, Tanabe Y, Kodama M, Aizawa Y. Clinical characteristics, treatment, and outcome of tachycardia induced cardiomyopathy. Int Heart J 2008;49:39-47.
14. Dahl P, Danzi S, Klein I. Thyrotoxic cardiac disease. Curr Heart Fail Rep 2008;5:170-176.
15. Bezdah L, Slimene H, Kammoun M, Haddad A, Belhani A. Hypothyroid dilated cardiomyopathy. Ann Cardiol Angeiol 2004;53:217-220.
16. Giannuzzi P, Temporelli PL, Bosimini E, et al. Heterogeneity of left ventricular remodeling after acute myocardial infarction: Results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico-3 Echo Substudy. Am Heart J 2001;141:131-138.
17. Funaro S, La Torre G, Madonna M, et al. Incidence, determinants, and prognostic value of reverse left ventricular remodelling after primary percutaneous coronary intervention: Results of the Acute Myocardial Infarction Contrast Imaging (AMICI) multicenter study. Eur Heart J 2009;30:566-575.
18. Appleton DL, Abbate A, Biondi-Zoccai GGL. Late percutaneous coronary intervention for the totally occluded infarct-related artery: A meta-analysis of the effects on cardiac function and remodeling. Catheter Cardio Inte 2008;71:772-781.
19. Rahimtoola SH. The hibernating myocardium. Am Heart J 1989;117:211-221.
20. Dilsizian V, Bonow RO. Current diagnostic techniques of assessing myocardial viability in patients with hibernating and stunned myocardium. Circulation 1993;87:1-20.
21. Bonow RO. The hibernating myocardium: Implications for management of congestive heart failure. Am Journal Cardiol 1995;75:17A-25A.
22. Bellenger NG, Yousef Z, Rajappan K, Marber MS, Pennell DJ. Infarct zone viability influences ventricular remodelling after late recanalisation of an occluded infarct related artery. Heart 2005;91:478-483.
23. Cigarroa CG, deFilippi CR, Brickner ME, Alvarez LG, Wait MA, Grayburn PA. Dobutamine stress echocardiography identifies hibernating myocardium and predicts recovery of left ventricular function after coronary revascularization. Circulation 1993;88:430-436.
24. Afridi I, Kleiman NS, Raizner AE, Zoghbi WA. Dobutamine echocardiography in myocardial hibernation. Optimal dose and accuracy in predicting recovery of ventricular function after coronary angioplasty. Circulation 1995;91:663-670.
25. Kiat H, Berman DS, Maddahi J, De Yang L, Van Train K, Rozanski A, Friedman J. Late reversibility of tomographic myocardial thallium-201 defects: An accurate marker of myocardial viability. J Amer Coll Cardiol 1988;12:1456-1463.
26. Dilsizian V, Rocco TP, Freedman NM, Leon MB, Bonow RO. Enhanced detection of ischemic but viable myocardium by the reinjection of thallium after stress-redistribution imaging. N Engl J Med 1990;323:141-146.
27. Wu YW, Tadamura E, Yamamuro M, et al. Comparison of contrast-enhanced MRI with (18)F-FDG PET/201Tl SPECT in dysfunctional myocardium: Relation to early functional outcome after surgical revascularization in chronic ischemic heart disease. J Nucl Med 2007;48:1096-1103.
28. Skala T, Hutyra M, Vaclavik J, et al. Prediction of long-term reverse left ventricular remodeling after revascularization or medical treatment in patients with ischemic cardiomyopathy: A comparative study between SPECT and MRI. Int J Cardiovasc Imag 2010. doi:
29. Perrone-Filardi P, Bacharach SL, Dilsizian V, Maurea S, Frank JA, Bonow RO. Regional left ventricular wall thickening. Relation to regional uptake of 18fluorodeoxyglucose and 201Tl in patients with chronic coronary artery disease and left ventricular dysfunction. Circulation 1992;86:1125-1137.
30. Bonow RO, Dilsizian V, Cuocolo A, Bacharach SL. Identification of viable myocardium in patients with chronic coronary artery disease and left ventricular dysfunction. Comparison of thallium scintigraphy with reinjection and PET imaging with 18F-fluorodeoxyglucose. Circulation 1991;83:26-37.
31. Chaudhry FA, Tauke JT, Alessandrini RS, Vardi G, Parker MA, Bonow RO. Prognostic implications of myocardial contractile reserve in patients with coronary artery disease and left ventricular dysfunction. J Am Coll Cardiol 1999;34:730-738.
32. Cwajg JM, Cwajg E, Nagueh SF, et al. End-diastolic wall thickness as a predictor of recovery of function in myocardial hibernation: Relation to rest-redistribution Tl-201 tomography and dobutamine stress echocardiography. J Am Coll Cardiol 2000;35:1152-1161.
33. Rizzello V, Bax JJ, Schinkel AF, et al. Does resting two-dimensional echocardiography identify patients with ischemic cardiomyopathy and low likelihood of functional recovery after coronary revascularization? Coronary Artery Dis 2004;15:269-275.
34. Domanski MJ, Krause-Steinrauf H, Massie BM, et al. A comparative analysis of the results from 4 trials of beta-blocker therapy for heart failure: BEST, CIBIS-II, MERIT-HF, and COPERNICUS. J Card Fail 2003;9:354-363.
35. MERIT-HT Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999;353:2001-2007.
36. McKelvie RS, Yusuf S, Pericak D, et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure: Randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. Circulation 1999;100:1056-1064.
37. Doughty RN, Whalley GA, Gamble G, MacMahon S, Sharpe N. Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease. Australia-New Zealand Heart Failure Research Collaborative Group. J Am Coll Cardiol 1997;29:1060-1066.
38. Palazzuoli A, Bruni F, Puccetti L, Pastorelli M, Angori P, Pasqui AL, Auteri A. Effects of carvedilol on left ventricular remodeling and systolic function in elderly patients with heart failure. Eur J Heart Fail 2002;4:765-770.
39. Bristow MR, Gilbert EM, Abraham WT, et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. Circulation 1996;94:2807-2816.
40. Cleland JG, Pennell DJ, Ray SG, et al. Myocardial viability as a determinant of the ejection fraction response to carvedilol in patients with heart failure (CHRISTMAS trial): Randomised controlled trial. Lancet 2003;362:14-21.
41. Colucci WS, Kolias TJ, Adams KF, et al. Metoprolol reverses left ventricular remodeling in patients with asymptomatic systolic dysfunction: The REversal of VEntricular Remodeling with Toprol-XL (REVERT) trial. Circulation 2007;116:49-56.
42. Torp-Pedersen C, Poole-Wilson PA, Swedberg K, et al. Effects of metoprolol and carvedilol on cause-specific mortality and morbidity in patients with chronic heart failure-COMET. Am Heart J 2005;149:370-376.
43. Packer M, Antonopoulos GV, Berlin JA, Chittams J, Konstam MA, Udelson JE. Comparative effects of carvedilol and metoprolol on left ventricular ejection fraction in heart failure: Results of a meta-analysis. Am Heart J 2001;141:899-907.
44. Reiken S, Wehrens XH, Vest JA, et al. Beta-blockers restore calcium release channel function and improve cardiac muscle performance in human heart failure. Circulation 2003;107:2459-2466.
45. Kubo H, Margulies KB, Piacentino V, 3rd, Gaughan JP, Houser SR. Patients with end-stage congestive heart failure treated with beta-adrenergic receptor antagonists have improved ventricular myocyte calcium regulatory protein abundance. Circulation 2001;104:1012-1018.
46. Gwathmey JK, Kim CS, Hajjar RJ, Khan F, DiSalvo TG, Matsumori A, Bristow MR. Cellular and molecular remodeling in a heart failure model treated with the beta-blocker carteolol. Am J Physiol 1999;276:H1678-H1690.
47. Pat B, Killingsworth C, Denney T, et al. Dissociation between cardiomyocyte function and remodeling with beta-adrenergic receptor blockade in isolated canine mitral regurgitation. Am J Physiol 2008;295:H2321-2327.
48. Wang R, Miura T, Harada N, et al. Pleiotropic effects of the beta-adrenoceptor blocker carvedilol on calcium regulation during oxidative stress-induced apoptosis in cardiomyocytes. J Pharmacol Exp Ther 2006;318:45-52.
49. Bartholomeu JB, Vanzelli AS, Rolim NP, et al. Intracellular mechanisms of specific beta-adrenoceptor antagonists involved in improved cardiac function and survival in a genetic model of heart failure. J Mol Cell Cardiol 2008;45:240-249.
50. St John Sutton M, Lee D, Rouleau JL, Goldman S, Plappert T, Braunwald E, Pfeffer MA. Left ventricular remodeling and ventricular arrhythmias after myocardial infarction. Circulation 2003;107:2577-2582.
51. Danser AH, van Kesteren CA, Bax WA, Tavenier M, Derkx FH, Saxena PR, Schalekamp MA. Prorenin, renin, angiotensinogen, and angiotensin-converting enzyme in normal and failing human hearts. Evidence for renin binding. Circulation 1997;96:220-226.
52. Greenberg B, Quinones MA, Koilpillai C, Limacher M, Shindler D, Benedict C, Shelton B. Effects of long-term enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction. Results of the SOLVD echocardiography substudy. Circulation 1995;91:2573-2581.
53. Wong M, Staszewsky L, Latini R, et al. Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study. J Am Coll Cardiol 2002;40:970-975.
54. Granger CB, McMurray JJ, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: The CHARM-Alternative trial. Lancet 2003;362:772-776.
55. Chan AK, Sanderson JE, Wang T, et al. Aldosterone receptor antagonism induces reverse remodeling when added to angiotensin receptor blockade in chronic heart failure. J Am Coll Cardiol 2007;50:591-596.
56. Nakatani S, Thomas JD, Savage RM, Vargo RL, Smedira NG, McCarthy PM. Prediction of right ventricular dysfunction after left ventricular assist device implantation. Circulation 1996;94:II216-II221.
57. James KB, McCarthy PM, Thomas JD, Vargo R, Hobbs RE, Sapp S, Bravo E. Effect of implantable LEVT ventricular assist device on neuroendocrine activation in heart failure. Circulation 1995;92:II191-II195.
58. Zafeiridis A, Jeevanandam V, Houser SR, Margulies KB. Regression of cellular hypertrophy after left ventricular assist device support. Circulation 1998;98:656-662.
59. Dipla K, Mattiello JA, Jeevanandam V, Houser SR, Margulies KB. Myocyte recovery after mechanical circulatory support in humans with end-stage heart failure. Circulation 1998;97:2316-2322.
60. Chaudhary KW, Rossman EI, Piacentino V, 3rd, et al. Altered myocardial Ca2 +cycling after left ventricular assist device support in the failing human heart. J Am Coll Cardiol 2004;44:837-845.
61. Klotz S, Barbone A, Reiken S, et al. Left ventricular assist device support normalizes left and right ventricular beta-adrenergic pathway properties. J Am Coll Cardiol 2005;45:668-676.
62. Harding JD, Piacentino V, 3rd, Gaughan JP, Houser SR, Margulies KB. Electrophysiological alterations after mechanical circulatory support in patients with advanced cardiac failure. Circulation 2001;104:1241-1247.
63. Klotz S, Foronjy RF, Dickstein ML, et al. Mechanical unloading during left ventricular assist device support increases left ventricular collagen cross-linking and myocardial stiffness. Circulation 2005;112:364-374.
64. Flesch M, Margulies KB, Mochmann HC, Engel D, Sivasubramanian N, Mann DL. Differential regulation of mitogen-activated protein kinases in the failing human heart in response to mechanical unloading. Circulation 2001;104:2273-2276.
65. Torre-Amione G, Stetson SJ, Youker KA, et al. Decreased expression of tumor necrosis factor-alpha in failing human myocardium after mechanical circulatory support: A potential mechanism for cardiac recovery. Circulation 1999;100:1189-1193.
66. Margulies KB, Matiwala S, Cornejo C, Olsen H, Craven WA, Bednarik D. Mixed messages: Transcription patterns in failing and recovering human myocardium. Circ Res 2005;96:592-599.
67. Matkovich SJ, Van Booven DJ, Youker KA, et al. Reciprocal regulation of myocardial microRNAs and messenger RNA in human cardiomyopathy and reversal of the microRNA signature by biomechanical support. Circulation 2009;119:1263-1271.
68. Maybaum S, Mancini D, Xydas S, et al. Cardiac improvement during mechanical circulatory support: A prospective multicenter study of the LVAD Working Group. Circulation 2007;115:2497-2505.
69. Chen X, Piacentino V, 3rd, Furukawa S, Goldman B, Margulies KB, Houser SR. L-type Ca2+ channel density and regulation are altered in failing human ventricular myocytes and recover after support with mechanical assist devices. Circ Res 2002;91:517-524.
70. Rossman EI, Petre RE, Chaudhary KW, et al. Abnormal frequency-dependent responses represent the pathophysiologic signature of contractile failure in human myocardium. J Mol Cell Cardiol 2004;36:33-42.
71. Heerdt PM, Klotz S, Burkhoff D. Cardiomyopathic etiology and SERCA2a reverse remodeling during mechanical support of the failing human heart. Anesth Analg 2006;102:32-37.
72. Ogletree-Hughes ML, Stull LB, Sweet WE, Smedira NG, McCarthy PM, Moravec CS. Mechanical unloading restores beta-adrenergic responsiveness and reverses receptor downregulation in the failing human heart. Circulation 2001;104:881-886.
73. Burkhoff D, Klotz S, Mancini DM. LVAD-induced reverse remodeling: Basic and clinical implications for myocardial recovery. J Cardiac Fail 2006;12:227-239.
74. Margulies KB. Reversal mechanisms of left ventricular remodeling: Lessons from left ventricular assist device experiments. J Cardiac Fail 2002;8:S500-S505.
75. Maybaum S, Kamalakannan G, Murthy S. Cardiac recovery during mechanical assist device support. Semin Thorac Cardiovasc Surg 2008;20:234-246.
76. Barbone A, Holmes JW, Heerdt PM, et al. Comparison of right and left ventricular responses to left ventricular assist device support in patients with severe heart failure: A primary role of mechanical unloading underlying reverse remodeling. Circulation 2001;104:670-675.
77. Mancini DM, Beniaminovitz A, Levin H, et al. Low incidence of myocardial recovery after left ventricular assist device implantation in patients with chronic heart failure. Circulation 1998;98:2383-2389.
78. Hetzer R, Muller JH, Weng Y, Meyer R, Dandel M. Bridging-to-recovery. Ann Thorac Surg 2001;71:S109-S113.
79. Birks EJ, Tansley PD, Hardy J, et al. Left ventricular assist device and drug therapy for the reversal of heart failure. N Engl J Med 2006;355:1873-1884.
80. Ukkonen H, Beanlands RSB, Burwash IG, et al. Effect of cardiac resynchronization on myocardial efficiency and regional oxidative metabolism. Circulation 2003;107:28-31.
81. Young JB, Abraham WT, Smith AL, et al. Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: The MIRACLE ICD Trial. JAMA 2003;289:2685-2694.
82. Duncan A, Wait D, Gibson D, Daubert JC. Left ventricular remodelling and haemodynamic effects of multisite biventricular pacing in patients with left ventricular systolic dysfunction and activation disturbances in sinus rhythm: Sub-study of the MUSTIC (Multisite Stimulationin Cardiomyopathies) trial. Eur Heart J 2003;24:430-441.
83. Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, Tavazzi L. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005;352:1539-1549.
84. St. John Sutton M, Ghio S, Plappert T, et al.; on Behalf of the REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction Study Group. Cardiac resynchronization induces major structural and functional reverse remodeling in patients with New York Heart Association class I/II heart failure. Circulation 2009;120:1858-1865.
85. Daubert C, Gold MR, Abraham WT, et al. Prevention of disease progression by cardiac resynchronization therapy in patients with asymptomatic or mildly symptomatic left ventricular dysfunction: Insights from the European cohort of the REVERSE (Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction) trial. J Am Coll Cardiol 2009;54:1837-1846.
86. Moss AJ, Hall WJ, Cannom DS, et al. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med 2009;361:1329-1338.
87. Kaneko Y, Floras JS, Usui K, et al. Cardiovascular effects of continuous positive airway pressure in patients with heart failure and obstructive sleep apnea. N Engl J Med 2003;348:1233-1241.
88. Mansfield DR, Gollogly NC, Kaye DM, Richardson M, Bergin P, Naughton MT. Controlled trial of continuous positive airway pressure in obstructive sleep apnea and heart failure. Am J Respir Crit Care Med 2004;169:361-366.
89. Trichon BH, Felker GM, Shaw LK, Cabell CH, O'Connor CM. Relation of frequency and severity of mitral regurgitation to survival among patients with left ventricular systolic dysfunction and heart failure. Am J Cardiol 2003;91:538-543.
90. Gorman JH, 3rd, Gorman RC. Surgical therapy for mitral regurgitation: The key to preventing heart failure? Curr Heart Fail Rep 2008;5:211-215.
91. Geidel S, Lass M, Schneider C, Groth G, Boczor S, Kuck KH, Ostermeyer J. Downsizing of the mitral valve and coronary revascularization in severe ischemic mitral regurgitation results in reverse left ventricular and left atrial remodeling. Eur J Cardiothorac Surg 2005;27:1011-1016.
92. Westenberg JJ, Braun J, Van de Veire NR, et al. Magnetic resonance imaging assessment of reverse left ventricular remodeling late after restrictive mitral annuloplasty in early stages of dilated cardiomyopathy. J Thorac Cardiovasc Surg 2008;135:1247-1252.
93. Bolling SF, Deeb GM, Brunsting LA, Bach DS. Early outcome of mitral valve reconstruction in patients with end-stage cardiomyopathy. J Thorac Cardiovasc Surg 1995;109:676-682; discussion 682-673.
94. Feldman T, Kar S, Rinaldi M, et al. Percutaneous mitral repair with the MitraClip system: Safety and midterm durability in the initial EVEREST (Endovascular Valve Edge-to-Edge REpair Study) cohort. J Am Coll Cardiol 2009;54:686-694.
95. Hermiller J. Percutaneous mitral repair with the MitraClip® device for functional mitral regurgitation: Acute success, one year durability and reverse remodeling in the initial EVEREST Cohort. In: American College of Cardiology Scientific Sessions/i2 Summit-SCAI Annual Meeting Chicago, IL, 2008.
96. Hung J, Papakostas L, Tahta SA, Hardy BG, Bollen BA, Duran CM, Levine RA. Mechanism of recurrent ischemic mitral regurgitation after annuloplasty: Continued LV remodeling as a moving target. Circulation 2004;110:II-85-90.
97. Poulsen SH, Sogaard P, Nielsen-Kudsk JE, Egeblad H. Recovery of left ventricular systolic longitudinal strain after valve replacement in aortic stenosis and relation to natriuretic peptides. J Am Soc Echocardiogr 2007;20:877-884.
98. Iwahashi N, Nakatani S, Kanzaki H, Hasegawa T, Abe H, Kitakaze M. Acute improvement in myocardial function assessed by myocardial strain and strain rate after aortic valve replacement for aortic stenosis. J Am Soc Echocardiogr 2006;19:1238-1244.
99. Biederman RW, Doyle M, Yamrozik J, et al. Physiologic compensation is supranormal in compensated aortic stenosis: Does it return to normal after aortic valve replacement or is it blunted by coexistent coronary artery disease? An intramyocardial magnetic resonance imaging study. Circulation 2005;112(9 Suppl):I429-I436.
100. Starling RC, Jessup M, Oh JK, Sabbah HN, Acker MA, Mann DL, Kubo SH. Sustained benefits of the CorCap Cardiac Support Device on left ventricular remodeling: Three year follow-up results from the Acorn clinical trial. Ann Thorac Surg 2007;84:1236-1242.
101. Chaudhry PA, Mishima T, Sharov VG, Hawkins J, Alferness C, Paone G, Sabbah HN. Passive epicardial containment prevents ventricular remodeling in heart failure. Ann Thorac Surg 2000;70:1275-1280.
102. Sabbah HN, Sharov VG, Gupta RC, et al. Reversal of chronic molecular and cellular abnormalities due to heart failure by passive mechanical ventricular containment. Circ Res 2003;93:1095-1101.
103. Sabbah HN, Gupta RC, Sharov VG, Todor A, Mishra S, Chaudhry PA, Nair H. Prevention of progressive left ventricular dilation with the Acorn cardiac support device (CSD) downregulates stretch-mediated p21ras, attenuates myocyte hypertrophy and improves sarcoplasmic reticulum calcium cycling in dogs with heart failure. Circulation 2000;102:683.
104. Jones RH, Velazquez EJ, Michler RE, et al. Coronary bypass surgery with or without surgical ventricular reconstruction. N Engl J Med 2009;360:1705-1717.
105. Batista RJ, Santos JL, Takeshita N, Bocchino L, Lima PN, Cunha MA. Partial left ventriculectomy to improve left ventricular function in end-stage heart disease. J Card Surg 1996;11:96-97.
106. McCarthy JF, McCarthy PM, Starling RC, et al. Partial left ventriculectomy and mitral valve repair for end-stage congestive heart failure. Eur J Cardiothorac Surg 1998;13:337-343.
107. Athanasuleas CL, Stanley AW, Jr, Buckberg GD, Dor V, DiDonato M, Blackstone EH. Surgical anterior ventricular endocardial restoration (SAVER) in the dilated remodeled ventricle after anterior myocardial infarction. RESTORE group. Reconstructive Endoventricular Surgery, returning Torsion Original Radius Elliptical Shape to the LV. J Am Coll Cardiol 2001;37:1199-1209.
108. Buckberg GD, Athanasuleas CL. The STICH trial: Misguided conclusions. J Thorac Cardiov Surg 2009;138:1060-1064, e1062.
109. Conte J. An indictment of the STICH trial: "True, true, and unrelated." J Heart Lung Transpl 29:491-496.
110. Menzel T, Wagner S, Kramm T, Mohr-Kahaly S, Mayer E, Braeuninger S, Meyer J. Pathophysiology of impaired right and left ventricular function in chronic embolic pulmonary hypertension: Changes after pulmonary thromboendarterectomy. Chest 2000;118:897-903.
111. Reesink HJ, Marcus JT, Tulevski II, Jamieson S, Kloek JJ, Vonk Noordegraaf A, Bresser P. Reverse right ventricular remodeling after pulmonary endarterectomy in patients with chronic thromboembolic pulmonary hypertension: Utility of magnetic resonance imaging to demonstrate restoration of the right ventricle. J Thorac Cardiov Sur 2007;133:58-64.
112. D'Armini AM, Zanotti G, Ghio S, et al. Reverse right ventricular remodeling after pulmonary endarterectomy. J Thorac Cardiov Sur 2007;133:162-168.
113. Kasimir MT, Seebacher G, Jaksch P, et al. Reverse cardiac remodelling in patients with primary pulmonary hypertension after isolated lung transplantation. Eur J Cardio-Thorac 2004;26:776-781.
114. Buechel ER, Dave HH, Kellenberger CJ, Dodge-Khatami A, Pretre R, Berger F, Bauersfeld U. Remodelling of the right ventricle after early pulmonary valve replacement in children with repaired tetralogy of Fallot: Assessment by cardiovascular magnetic resonance. Eur Heart J 2005;26:2721-2727.
115. Mukherjee D, Nader S, Olano A, Garcia MJ, Griffin BP. Improvement in right ventricular systolic function after surgical correction of isolated tricuspid regurgitation. J Am Soc Echocardiogr 2000;13:650-654.
116. Galie N, Hinderliter AL, Torbicki A, et al. Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and Doppler measures in patients with pulmonary arterial hypertension. J Am Coll Cardiol 2003;41:1380-1386.
117. Lampert MB, Weinert L, Hibbard J, Korcarz C, Lindheimer M, Lang RM. Contractile reserve in patients with peripartum cardiomyopathy and recovered left ventricular function. Am J Obstet Gynecol 1997;176:189-195.
118. Hershman DL, Shao T. Anthracycline cardiotoxicity after breast cancer treatment. Oncology (Williston Park) 2009;23:227-234.
119. Brandt RR, Reiner C, Arnold R, Sperzel J, Pitschner HF, Hamm CW. Contractile response and mitral regurgitation after temporary interruption of long-term cardiac resynchronization therapy. Eur Heart J 2006;27:187-192.
120. Morimoto S, Shimizu K, Yamada K, Hiramitsu S, Hishida H. Can beta-blocker therapy be withdrawn from patients with dilated cardiomyopathy? Am Heart J 1999;138:456-459.